Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas

被引：16

作者：

Alhalabi, Omar ^{[1
]}

Thouvenin, Jonathan ^{[2
,3
]}

Negrier, Sylvie ^{[4
]}

Vano, Yann-Alexandre ^{[5
]}

Campedel, Luca ^{[6
]}

Hasanov, Elshad ^{[1
]}

Bakouny, Ziad ^{[7
,8
]}

Hahn, Andrew W. ^{[1
]}

Bilen, Mehmet Asim ^{[9
]}

Msaouel, Pavlos ^{[1
]}

Choueiri, Toni K. ^{[7
]}

Viswanathan, Srinivas R. ^{[7
]}

Sircar, Kanishka ^{[1
]}

Albiges, Laurence ^{[10
]}

Malouf, Gabriel G.

Tannir, Nizar M. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Inst Cancerol Hosp Civils Lyon, Lyon, France

[3] Inst Cancerol Strasbourg Europe ICANS HUS, Strasbourg, France

[4] Univ Lyon 1, Ctr Leon Berard, Lyon, France

[5] Hop Europe Georges Pompidou, AP HP, Inst Canc Paris CARPEM, Ctr Univ Paris, Paris, France

[6] Grp Hosp Pitie Salpetriere, AP HP, Paris, France

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[9] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[10] Inst Gustave Roussy, Villejuif, France

来源：

ONCOLOGIST | 2023年 / 28卷 / 05期

关键词：

MiT family translocation renal cell carcinoma; immunotherapy; non-clear cell renal cell carcinoma; FEATURES; RCC;

D O I：

10.1093/oncolo/oyac262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: There remains a paucity of data regarding the efficacy of immune checkpoint therapy (ICT) combinations +/- vascular endothelial growth factor (VEGF) targeted therapy (TT) in translocation renal cell carcinoma (tRCC). Methods: This is a retrospective study of patients with advanced tRCC treated with ICT combinations at 11 centers in the US, France, and Belgium. Only cases with confirmed fluorescence in situ hybridization (FISH) were included. Objective response rates (ORR) and progression-free survival (PFS) were assessed by RECIST, and overall survival (OS) was estimated by Kaplan-Meier methods. Results: There were 29 patients identified with median age of 38 (21-70) years, and F:M ratio 0.9:1. FISH revealed TFE3 and TFEB translocations in 22 and 7 patients, respectively. Dual ICT and ICT + VEGF TT were used in 18 and 11 patients, respectively. Seventeen (59%) patients received ICT combinations as first-line therapy. ORR was 1/18 (5.5%) for dual ICT and 4/11 (36%) for ICT + VEGF TT. At a median follow-up of 12.9 months, median PFS was 2.8 and 5.4 months in the dual ICT and ICT + VEGF TT groups, respectively. Median OS from metastatic disease was 17.8 and 30.7 months in the dual ICT and ICT + VEGF TT groups, respectively. Conclusion: In this retrospective study of advanced tRCC, limited response and survival were seen after frontline dual ICT combination therapy, while ICT + VEGF TT therapy offered some efficacy. Due to the heterogeneity of tRCC, insights into the biological underpinnings are necessary to develop more effective therapies.

引用

页码：433 / 439

页数：7

共 25 条

[1] MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers [J].

Alhalabi, Omar ;

Chen, Jianfeng ;

Zhang, Yuxue ;

Lu, Yang ;

Wang, Qi ;

Ramachandran, Sumankalai ;

Tidwell, Rebecca Slack ;

Han, Guangchun ;

Yan, Xinmiao ;

Meng, Jieru ;

Wang, Ruiping ;

Hoang, Anh G. ;

Wang, Wei-Lien ;

Song, Jian ;

Lopez, Lidia ;

Andreev-Drakhlin, Alex ;

Siefker-Radtke, Arlene ;

Zhang, Xinqiao ;

Benedict, William F. ;

Shah, Amishi Y. ;

Wang, Jennifer ;

Msaouel, Pavlos ;

Zhang, Miao ;

Guo, Charles C. ;

Czerniak, Bogdan ;

Behrens, Carmen ;

Soto, Luisa ;

Papadimitrakopoulou, Vassiliki ;

Lewis, Jeff ;

Rinsurongkawong, Waree ;

Rinsurongkawong, Vadeerat ;

Lee, Jack ;

Roth, Jack ;

Swisher, Stephen ;

Wistuba, Ignacio ;

Heymach, John ;

Wang, Jing ;

Campbell, Matthew T. ;

Efstathiou, Eleni ;

Titus, Mark ;

Logothetis, Christopher J. ;

Ho, Thai H. ;

Zhang, Jianjun ;

Wang, Linghua ;

Gao, Jianjun .

NATURE COMMUNICATIONS, 2022, 13 (01)

[2] Integrative clinical and molecular characterization of translocation renal cell carcinoma [J].

Bakouny, Ziad ;

Sadagopan, Ananthan ;

Ravi, Praful ;

Metaferia, Nebiyou Y. ;

Li, Jiao ;

AbuHammad, Shatha ;

Tang, Stephen ;

Denize, Thomas ;

Garner, Emma R. ;

Gao, Xin ;

Braun, David A. ;

Hirsch, Laure ;

Steinharter, John A. ;

Bouchard, Gabrielle ;

Walton, Emily ;

West, Destiny ;

Labaki, Chris ;

Dudani, Shaan ;

Gan, Chun-Loo ;

Sethunath, Vidyalakshmi ;

Carvalho, Filipe L. F. ;

Imamovic, Alma ;

Ricker, Cora ;

Vokes, Natalie, I ;

Nyman, Jackson ;

Berchuck, Jacob E. ;

Park, Jihye ;

Hirsch, Michelle S. ;

Haq, Rizwan ;

Lee, Gwo-Shu Mary ;

McGregor, Bradley A. ;

Chang, Steven L. ;

Feldman, Adam S. ;

Wu, Catherine J. ;

McDermott, David F. ;

Heng, Daniel Y. C. ;

Signoretti, Sabina ;

Van Allen, Eliezer M. ;

Choueiri, Toni K. ;

Viswanathan, Srinivas R. .

CELL REPORTS, 2022, 38 (01)

[3] Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders [J].

Boileve, A. ;

Carlo, M. I. ;

Barthelemy, P. ;

Oudard, S. ;

Borchiellini, D. ;

Voss, M. H. ;

George, S. ;

Chevreau, C. ;

Landman-Parker, J. ;

Tabone, M-D ;

Chism, D. D. ;

Amin, A. ;

Bilen, M. A. ;

Bosse, D. ;

Coulomb-L'hermine, A. ;

Su, Xiaoping ;

Choueiri, T. K. ;

Tannir, Nizar M. ;

Malouf, Gabriel G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[4] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events [J].

Brahmer, Julie R. ;

Abu-Sbeih, Hamzah ;

Ascierto, Paolo Antonio ;

Brufsky, Jill ;

Cappelli, Laura C. ;

Cortazar, Frank B. ;

Gerber, David E. ;

Hamad, Lamya ;

Hansen, Eric ;

Johnson, Douglas B. ;

Lacouture, Mario E. ;

Masters, Gregory A. ;

Naidoo, Jarushka ;

Nanni, Michele ;

Perales, Miguel-Angel ;

Puzanov, Igor ;

Santomasso, Bianca D. ;

Shanbhag, Satish P. ;

Sharma, Rajeev ;

Skondra, Dimitra ;

Sosman, Jeffrey A. ;

Turner, Michelle ;

Ernstoff, Marc S. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)

[5] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[6] Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Adult Metastatic Xp11.2 Translocation Renal Cell Carcinoma [J].

Choueiri, Toni K. ;

Lim, Zita Dubauskas ;

Hirsch, Michelle S. ;

Tamboli, Pheroze ;

Jonasch, Eric ;

McDermott, David F. ;

Dal Cin, Paola ;

Corn, Paul ;

Vaishampayan, Ulka ;

Heng, Daniel Y. C. ;

Tannir, Nizar M. .

CANCER, 2010, 116 (22) :5219-5225

[7] Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas [J].

Classe, Marion ;

Malouf, Gabriel G. ;

Su, Xiaoping ;

Yao, Hui ;

Thompson, Erika J. ;

Doss, Denaha J. ;

Gregoire, Valerie ;

Lenobin, Julien ;

Fantoni, Jean-Christophe ;

Sudour-Bonnange, Helene ;

Khayat, David ;

Aubert, Sebastien ;

Tannir, Nizar M. ;

Leroy, Xavier .

HISTOPATHOLOGY, 2017, 70 (07) :1089-1097

[8] Recommendations for the Management of Rare Kidney Cancers [J].

Giles, Rachel H. ;

Choueiri, Toni K. ;

Heng, Daniel Y. ;

Albiges, Laurence ;

Hsieh, James J. ;

Linehan, W. Marston ;

Pal, Sumanta ;

Maskens, Deborah ;

Paseman, Bill ;

Jonasch, Eric ;

Malouf, Gabriel ;

Molina, Ana M. ;

Pickering, Lisa ;

Shuch, Brian ;

Srinivas, Sandy ;

Srinivasan, Ramaprasad ;

Tannir, Nizar M. ;

Bex, Axel .

EUROPEAN UROLOGY, 2017, 72 (06) :974-983

[9] 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy [J].

Han, Guangchun ;

Yang, Guoliang ;

Hao, Dapeng ;

Lu, Yang ;

Thein, Kyaw ;

Simpson, Benjamin S. ;

Chen, Jianfeng ;

Sun, Ryan ;

Alhalabi, Omar ;

Wang, Ruiping ;

Dang, Minghao ;

Dai, Enyu ;

Zhang, Shaojun ;

Nie, Fengqi ;

Zhao, Shuangtao ;

Guo, Charles ;

Hamza, Ameer ;

Czerniak, Bogdan ;

Cheng, Chao ;

Siefker-Radtke, Arlene ;

Bhat, Krishna ;

Futreal, Andrew ;

Peng, Guang ;

Wargo, Jennifer ;

Peng, Weiyi ;

Kadara, Humam ;

Ajani, Jaffer ;

Swanton, Charles ;

Litchfield, Kevin ;

Ahnert, Jordi Rodon ;

Gao, Jianjun ;

Wang, Linghua .

NATURE COMMUNICATIONS, 2021, 12 (01)

[10] Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma [J].

Jang, Hee-Jin ;

Truong, Cynthia Y. ;

Lo, Eric M. ;

Holmes, Hudson M. ;

Ramos, Daniela ;

Ramineni, Maheshwari ;

Lee, Ju-Seog ;

Wang, Daniel Y. ;

Pietropaolo, Massimo ;

Ripley, R. Taylor ;

Burt, Bryan M. ;

Lee, Hyun-Sung .

ANNALS OF THORACIC SURGERY, 2022, 114 (05) :1842-1852

← 1 2 3 →